The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study
Identifieur interne : 002B43 ( Main/Corpus ); précédent : 002B42; suivant : 002B44The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study
Auteurs : Tanya Gurevich ; Chava Peretz ; Orna Moore ; Nina Weizmann ; Nir GiladiSource :
- Movement Disorders [ 0885-3185 ] ; 2007-04-30.
English descriptors
- KwdEn :
Abstract
Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients. Method: BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6‐month follow‐up). Results: Eleven age‐ and disease severity‐matched PD patients with disabling FOG participated. Six patients received BTX‐A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX‐A injections to the legs did not improve FOG and might increase fall risk. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21396
Links to Exploration step
ISTEX:6F3A511E37DFD18E49BDBCE13207147F990A0410Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title><author><name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Moore, Orna" sort="Moore, Orna" uniqKey="Moore O" first="Orna" last="Moore">Orna Moore</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Weizmann, Nina" sort="Weizmann, Nina" uniqKey="Weizmann N" first="Nina" last="Weizmann">Nina Weizmann</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6F3A511E37DFD18E49BDBCE13207147F990A0410</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21396</idno><idno type="url">https://api.istex.fr/document/6F3A511E37DFD18E49BDBCE13207147F990A0410/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002B43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title><author><name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Moore, Orna" sort="Moore, Orna" uniqKey="Moore O" first="Orna" last="Moore">Orna Moore</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Weizmann, Nina" sort="Weizmann, Nina" uniqKey="Weizmann N" first="Nina" last="Weizmann">Nina Weizmann</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation><mods:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-30">2007-04-30</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="880">880</biblScope><biblScope unit="page" to="883">883</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6F3A511E37DFD18E49BDBCE13207147F990A0410</idno><idno type="DOI">10.1002/mds.21396</idno><idno type="ArticleID">MDS21396</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>botulinum toxin</term><term>falls</term><term>freezing of gait</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients. Method: BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6‐month follow‐up). Results: Eleven age‐ and disease severity‐matched PD patients with disabling FOG participated. Six patients received BTX‐A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX‐A injections to the legs did not improve FOG and might increase fall risk. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Tanya Gurevich MD</name><affiliations><json:string>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</json:string><json:string>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Chava Peretz PhD</name><affiliations><json:string>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</json:string><json:string>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Orna Moore RN, MA</name><affiliations><json:string>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Nina Weizmann MD</name><affiliations><json:string>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Nir Giladi MD</name><affiliations><json:string>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</json:string><json:string>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>botulinum toxin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>freezing of gait</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>falls</value></json:item></subject><articleId><json:string>MDS21396</json:string></articleId><language><json:string>eng</json:string></language><abstract>Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients. Method: BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6‐month follow‐up). Results: Eleven age‐ and disease severity‐matched PD patients with disabling FOG participated. Six patients received BTX‐A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX‐A injections to the legs did not improve FOG and might increase fall risk. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>4.093</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>695</abstractCharCount><pdfWordCount>2809</pdfWordCount><pdfCharCount>17123</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>107</abstractWordCount></qualityIndicators><title>The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>883</last><first>880</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21396</json:string></doi><id>6F3A511E37DFD18E49BDBCE13207147F990A0410</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6F3A511E37DFD18E49BDBCE13207147F990A0410/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6F3A511E37DFD18E49BDBCE13207147F990A0410/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6F3A511E37DFD18E49BDBCE13207147F990A0410/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><notesStmt><note>Allergan, USA</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title><author><persName><forename type="first">Tanya</forename><surname>Gurevich</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Chava</forename><surname>Peretz</surname></persName><roleName type="degree">PhD</roleName><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Orna</forename><surname>Moore</surname></persName><roleName type="degree">RN, MA</roleName><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Nina</forename><surname>Weizmann</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Nir</forename><surname>Giladi</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Movement Disorders Unit, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, Israel 64239</p></note><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-30"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="880">880</biblScope><biblScope unit="page" to="883">883</biblScope></imprint></monogr><idno type="istex">6F3A511E37DFD18E49BDBCE13207147F990A0410</idno><idno type="DOI">10.1002/mds.21396</idno><idno type="ArticleID">MDS21396</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients. Method: BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6‐month follow‐up). Results: Eleven age‐ and disease severity‐matched PD patients with disabling FOG participated. Six patients received BTX‐A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX‐A injections to the legs did not improve FOG and might increase fall risk. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>botulinum toxin</term></item><item><term>freezing of gait</term></item><item><term>Parkinson's disease</term></item><item><term>falls</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-12-06">Received</change><change when="2006-12-10">Registration</change><change when="2007-04-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6F3A511E37DFD18E49BDBCE13207147F990A0410/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v22:6</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2007-04-30">30 April 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="220" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21396</doi><idGroup><id type="unit" value="MDS21396"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-12-06"></event><event type="manuscriptAccepted" date="2006-12-10"></event><event type="firstOnline" date="2007-02-08"></event><event type="publishedOnlineFinalForm" date="2007-04-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-02-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">880</numbering><numbering type="pageLast">883</numbering></numberingGroup><correspondenceTo>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, Israel 64239</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21396.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="12"></count><count type="wordTotal" number="2569"></count></countGroup><titleGroup><title type="main" xml:lang="en">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title><title type="short" xml:lang="en">Botulinum Toxin for FOG in Parkinson′s Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Tanya</givenNames><familyName>Gurevich</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Chava</givenNames><familyName>Peretz</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Orna</givenNames><familyName>Moore</familyName><degrees>RN, MA</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Nina</givenNames><familyName>Weizmann</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Nir</givenNames><familyName>Giladi</familyName><degrees>MD</degrees></personName><contactDetails><email>nirg@tasmc.health.gov.il</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IL" type="organization"><unparsedAffiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IL" type="organization"><unparsedAffiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">botulinum toxin</keyword><keyword xml:id="kwd2">freezing of gait</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">falls</keyword></keywordGroup><fundingInfo><fundingAgency>Allergan, USA</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Objective</title><p>To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients.</p></section><section xml:id="abs1-2"><title type="main">Method</title><p>BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6‐month follow‐up).</p></section><section xml:id="abs1-3"><title type="main">Results</title><p>Eleven age‐ and disease severity‐matched PD patients with disabling FOG participated. Six patients received BTX‐A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination.</p></section><section xml:id="abs1-4"><title type="main">Conclusion</title><p>BTX‐A injections to the legs did not improve FOG and might increase fall risk. © 2007 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Botulinum Toxin for FOG in Parkinson′s Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study</title></titleInfo><name type="personal"><namePart type="given">Tanya</namePart><namePart type="family">Gurevich</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chava</namePart><namePart type="family">Peretz</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Orna</namePart><namePart type="family">Moore</namePart><namePart type="termsOfAddress">RN, MA</namePart><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nina</namePart><namePart type="family">Weizmann</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nir</namePart><namePart type="family">Giladi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel‐Aviv Sourasky Medical Center, Tel‐Aviv, Israel</affiliation><affiliation>Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation><description>Correspondence: Movement Disorders Unit, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, Israel 64239</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-04-30</dateIssued><dateCaptured encoding="w3cdtf">2006-12-06</dateCaptured><dateValid encoding="w3cdtf">2006-12-10</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">12</extent><extent unit="words">2569</extent></physicalDescription><abstract lang="en">Objective: To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients. Method: BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6‐month follow‐up). Results: Eleven age‐ and disease severity‐matched PD patients with disabling FOG participated. Six patients received BTX‐A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination. Conclusion: BTX‐A injections to the legs did not improve FOG and might increase fall risk. © 2007 Movement Disorder Society</abstract><note type="funding">Allergan, USA</note><subject lang="en"><genre>Keywords</genre><topic>botulinum toxin</topic><topic>freezing of gait</topic><topic>Parkinson's disease</topic><topic>falls</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>880</start><end>883</end><total>4</total></extent></part></relatedItem><identifier type="istex">6F3A511E37DFD18E49BDBCE13207147F990A0410</identifier><identifier type="DOI">10.1002/mds.21396</identifier><identifier type="ArticleID">MDS21396</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002B43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:6F3A511E37DFD18E49BDBCE13207147F990A0410
|texte= The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study
}}
| This area was generated with Dilib version V0.6.23. |  |